BACKGROUND: It is postulated that high serum levels of insulin and insulin growth factor 1 (IGF-1) mediate obesity-associated carcinogenesis. The relationship of insulin, IGF-1 and IGF binding proteins (IGFBP) with Barrett's oesophagus (BO) has not been well examined. METHODS: Serum levels of insulin and IGFBPs in patients with BO were compared with two separate control groups: subjects with gastro-oesophageal reflux disease (GORD) and screening colonoscopy controls. Fasting insulin, IGF-1 and IGFBPs were assayed in the serum of BO cases (n = 135), GORD (n = 135) and screening colonoscopy (n = 932) controls recruited prospectively at two academic hospitals. Logistic regression was used to estimate the risk of BO. RESULTS: Patients in the highest tertile of serum insulin levels had an increased risk of BO compared with colonoscopy controls (adjusted OR 2.02, 95% CI 1.15 to 3.54) but not compared with GORD controls (adjusted OR 1.55, 95% CI 0.76 to 3.15). Serum IGF-1 levels in the highest tertile were associated with an increased risk of BO (adjusted OR 4.05, 95% CI 2.01 to 8.17) compared with the screening colonoscopy control group but were not significantly different from the GORD control group (adjusted OR 0.57, 95% CI 0.27 to 1.17). IGFBP-1 levels in the highest tertile were inversely associated with a risk of BO in comparison with the screening colonoscopy controls (adjusted OR 0.11, 95% CI 0.05 to 0.24) but were not significantly different from the GORD control group (adjusted OR 1.04, 95% CI 0.49 to 2.16). IGFBP-3 levels in the highest tertile were inversely associated with the risk of BO compared with the GORD controls (OR 0.36, 95% CI 0.16 to 0.81) and also when compared with the colonoscopy controls (OR 0.40, 95% CI 0.20 to 0.79). CONCLUSIONS: These results provide support for the hypothesis that the insulin/IGF signalling pathways have a role in the development of BO.
BACKGROUND: It is postulated that high serum levels of insulin and insulin growth factor 1 (IGF-1) mediate obesity-associated carcinogenesis. The relationship of insulin, IGF-1 and IGF binding proteins (IGFBP) with Barrett's oesophagus (BO) has not been well examined. METHODS: Serum levels of insulin and IGFBPs in patients with BO were compared with two separate control groups: subjects with gastro-oesophageal reflux disease (GORD) and screening colonoscopy controls. Fasting insulin, IGF-1 and IGFBPs were assayed in the serum of BO cases (n = 135), GORD (n = 135) and screening colonoscopy (n = 932) controls recruited prospectively at two academic hospitals. Logistic regression was used to estimate the risk of BO. RESULTS:Patients in the highest tertile of serum insulin levels had an increased risk of BO compared with colonoscopy controls (adjusted OR 2.02, 95% CI 1.15 to 3.54) but not compared with GORD controls (adjusted OR 1.55, 95% CI 0.76 to 3.15). Serum IGF-1 levels in the highest tertile were associated with an increased risk of BO (adjusted OR 4.05, 95% CI 2.01 to 8.17) compared with the screening colonoscopy control group but were not significantly different from the GORD control group (adjusted OR 0.57, 95% CI 0.27 to 1.17). IGFBP-1 levels in the highest tertile were inversely associated with a risk of BO in comparison with the screening colonoscopy controls (adjusted OR 0.11, 95% CI 0.05 to 0.24) but were not significantly different from the GORD control group (adjusted OR 1.04, 95% CI 0.49 to 2.16). IGFBP-3 levels in the highest tertile were inversely associated with the risk of BO compared with the GORD controls (OR 0.36, 95% CI 0.16 to 0.81) and also when compared with the colonoscopy controls (OR 0.40, 95% CI 0.20 to 0.79). CONCLUSIONS: These results provide support for the hypothesis that the insulin/IGF signalling pathways have a role in the development of BO.
Authors: Zoe R Edelstein; Diana C Farrow; Mary P Bronner; Sheldon N Rosen; Thomas L Vaughan Journal: Gastroenterology Date: 2007-05-21 Impact factor: 22.682
Authors: Sid H Siahpush; Thomas L Vaughan; Johanna N Lampe; Robert Freeman; Skay Lewis; Robert D Odze; Patricia L Blount; Kamran Ayub; Peter S Rabinovitch; Brian J Reid; Chu Chen Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11 Impact factor: 4.254
Authors: Aoife M Ryan; Laura A Healy; Derek G Power; Miriam Byrne; Sinead Murphy; Patrick J Byrne; Dermot Kelleher; John V Reynolds Journal: Ann Surg Date: 2008-06 Impact factor: 12.969
Authors: Michael D Crowell; Angela Bradley; Stephanie Hansel; Paula Dionisio; Hack Jae Kim; G Anton Decker; John K DiBaise; V K Sharma Journal: Am J Gastroenterol Date: 2009-02-17 Impact factor: 10.864
Authors: Kimberley MacDonald; Geoffrey A Porter; Duane L Guernsey; Ronghua Zhao; Alan G Casson Journal: Cancer Epidemiol Date: 2009-05-28 Impact factor: 2.984
Authors: R E Neale; J D Doecke; N Pandeya; S Sadeghi; S Sadhegi; A C Green; P M Webb; D C Whiteman Journal: Br J Cancer Date: 2009-02-03 Impact factor: 7.640
Authors: Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi Journal: Gastroenterology Date: 2013-08-30 Impact factor: 22.682
Authors: Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer Journal: Clin Gastroenterol Hepatol Date: 2013-05-22 Impact factor: 11.382
Authors: Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2013-08-15 Impact factor: 11.382
Authors: Eric M Nelsen; Yujiro Kirihara; Naoki Takahashi; Qian Shi; Jason T Lewis; Vikneswaran Namasivayam; Navtej S Buttar; Kelly T Dunagan; Ganapathy A Prasad Journal: Clin Gastroenterol Hepatol Date: 2012-03-17 Impact factor: 11.382
Authors: M Q Chan; A E Blum; A K Chandar; A M L Kieber Emmons; Y Shindo; W Brock; G W Falk; M I Canto; J S Wang; P G Iyer; N J Shaheen; W M Grady; J A Abrams; P N Thota; K K Guda; A Chak Journal: Dis Esophagus Date: 2018-04-01 Impact factor: 3.429
Authors: Cadman L Leggett; Eric M Nelsen; Jianmin Tian; Cathy B Schleck; Alan R Zinsmeister; Kelly T Dunagan; G Richard Locke; Kenneth K Wang; Nicholas J Talley; Prasad G Iyer Journal: Mayo Clin Proc Date: 2013-02 Impact factor: 7.616